Multidrug therapy in leprosy can prevent relapse - A retrospective study

Indian Journal of Leprosy

Volumn 74, Issue 4, 2003, Pages 313-318

  Biswas, S ^a,b   Mondal, K K ^c,d  

^a IPGME and R ^*  (India)

^b Durgapur LCU   (India)

^c R G KAR MEDICAL COLLEGE   (India)

^d Gopalpur Leprosy Clinic   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; LEPROSTATIC AGENT;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; ERADICATION THERAPY; HEALTH PROGRAM; HUMAN; INDIA; LEPROSY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIBACILLARY LEPROSY; PAUCIBACILLARY LEPROSY; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION;

DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 0036825449     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Constant-Desporates M, Guelpa-Lauras CC, Carolina JC, et al. (1991). A case of relapse with drug-susceptible M. leprae after multidrug therapy. Int J Lepr 59: 242-7
2. Ganapati R, Bulchand HO, Pai VV, Kingsley S, Revankar CR. Relapsing multibacillary leprosy. Under publication. Int J Lepr.
3. Grugni A, Nadkarni NJ, Kini MS, Mehta VR (1990). Relapses in paucibacillary leprosy after MDT - A clinical study. Int J Lepr 58: 19-24
4. Jaggarajamma K, Thomas A, Nagarajan M (2000). Status of long absentees among multibacillary leprosy patients admitted to a controlled clinical study. Indian J Lepr 72: 469-75
5. Katoch K, Natarajan M, Bagga A, Katoch VM (1991). Clinical and bacteriological progress of highly bacillated BL - LL patients discontinuing treatment after different periods of MDT. Int J Lepr 59: 248-54
6. Katoch K, Natarajan M, Katoch VM et al. (1999). Chemotherapy trial in paucibacillary leprosy using clofazimine. Indian J Lepr 71: 311-24
7. Katoch K (2000). Therapeutic prospects for paucibacillary leprosy. Indian J Lepr 72: 351-61
8. Revankar CR, Pai VV, Chavan KJ, Dandekar AD, Ganapati R (1999). Identification of late clinical events after MDT in multibacillary leprosy. Souvenir-cum-Abstract Book. 21st Biennial Conference of the Indian Association of Leprologists, Chandigarh, 17-19 September 1999
9. Thomas A, Hari L, Nagarajan M, Prabhakar R (1995). Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; Case reports. Int J Lepr 63: 391-4
10. Umarane SB (2001). Relapse rates amongst the multidrug therapy-treated leprosy patients. Indian J Lepr 73: 362-3
11. WHO (1982). Chemotherapy of Leprosy for Control Programmes. Report of a WHO Study Group. WHO Technical Report Series, No 675. Geneva, World Health Organization
12. WHO (1988). WHO Expert Committee on Leprosy. Sixth report. WHO Technical Report Series, No 768. Geneva, World Health Organization
13. WHO (1994). Chemotherapy of leprosy. Report of a WHO Study Group. WHO Technical Report Series, No 847. Geneva, World Health Organization
14. WHO Leprosy Unit. (1994). Risk of Relapse in Leprosy. (Unpublished document, WHO/CTD/Lep/94.1). Geneva, World Health Organization
15. WHO Leprosy Unit (1995). Risk of relapse in leprosy. Symposium Paper. Indian J Lepr 67: 13-26
16. WHO (1998). WHO Expert Committee on Leprosy. Seventh report. WHO Technical Report Series, No 874. Geneva, World Health Organization